![Aptevo Therapeutics Inc](/common/images/company/N_APVO.png)
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed us... Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells. Show more
A Washington-based biotech company is already stealing the spotlight so far during Wednesday’s premarket after it was announced that the company closed a roughly $2.75 To read the full story...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1351 | 45.8121397084 | 0.2949 | 0.6559 | 0.285 | 67460769 | 0.57078706 | CS |
4 | -0.1092 | -20.2522255193 | 0.5392 | 0.6559 | 0.2848 | 18456355 | 0.56126753 | CS |
12 | -0.33 | -43.4210526316 | 0.76 | 1.38 | 0.2848 | 6887390 | 0.61259454 | CS |
26 | -6.8872 | -94.1234351938 | 7.3172 | 10.8 | 0.2848 | 3394023 | 0.91132098 | CS |
52 | -48.41 | -99.1195741196 | 48.84 | 50.16 | 0.2848 | 1914125 | 2.39015299 | CS |
156 | -922.25 | -99.9533966272 | 922.68 | 971.5156 | 0.2848 | 1047925 | 212.3166615 | CS |
260 | -38.3516 | -98.8912267673 | 38.7816 | 2640 | 0.2848 | 840855 | 282.3638449 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.